- Supported exchanges /
- LSE /
- BVX.LSE
BiVictriX Therapeutics PLC (BVX LSE) stock market data APIs
BiVictriX Therapeutics plc, a biotechnology company, engages in the research and experimental development of pharmaceutical products in the United Kingdom. The company develops Bi-Cygni, a proprietary platform that combines the discovery of novel, cancer-selective twin-antigen pairs or fingerprints with bispecific antibody engineering insights to create anti-cancer therapeutics. Its lead program is BVX001, a first-in-class Bi Cygni antibody drug conjugates to treat acute myeloid leukemia. The company also develops BVX002 for treating ovarian and other solid tumors; and BVX003 for bladder and other solid tumors. The company was formerly known as BiVictriX plc and changed its name to BiVictriX Therapeutics plc in August 2021. BiVictriX Therapeutics plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.
BiVictriX Therapeutics PLC Financial Data Overview
| 10 | |
| 8.625 | |
| - | |
| 10 | |
| 8.625 | |
| 7-14.25 | |
| 8 253 K | |
| 82 526 K | |
| 0 | |
| -0.02 | |
| -0.727 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
BiVictriX Therapeutics PLC Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -3 170 000
- Earnings Per Share -0.04
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get BiVictriX Therapeutics PLC Earnings via APIs
- Latest Release 2023-03-30
- EPS/Forecast NaN
Get BiVictriX Therapeutics PLC End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
